Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China
"The issuance of this patent further expands our worldwide patents protecting our proprietary, highly sensitive ctDNA platform technology into
"We are pleased to have obtained this additional patent protection for our unique and novel Target Selector™ ctDNA platform technology in an important territory," said
About Target Selector™ Technology
The "switch-blocker" technology covered by this patent, as well as the previously issued U.S. Patent No. 9,834,817, is applicable to a broad range of molecular genomic platforms, including real-time PCR, digital PCR,
In clinical validation studies,
About
Forward-Looking Statements Disclaimer Statement
This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend" or "project," or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements as to our ability to improve the outcomes of cancer patients, the utility and effectiveness of our intellectual property protections, the potential for
View original content with multimedia:http://www.prnewswire.com/news-releases/biocept-obtains-patent-for-its-target-selector-molecular-biomarker-technology-in-china-300621516.html
SOURCE
Investor Contact: LHA Investor Relations: Jody Cain, Jcain@lhai.com, 310-691-7100; Media Contact: Trevelino/Keller: Colleen Murphy, cmurphy@trevelinokeller.com, 404-214-0722, Ext. 109